Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery

The Journal of Pharmacy and Pharmacology
W-S V Ho, C Robin Hiley

Abstract

Virodhamine is a recently identified novel endocannabinoid. Cannabinoids may evoke vasorelaxation through novel receptors in the vasculature and/or through release of vasodilator peptides from sensory nerve endings. Virodhamine induced endothelium-dependent relaxation in the rat isolated small mesenteric artery mounted in a myograph and precontracted with methoxamine. Desensitization of vanilloid receptors by capsaicin did not affect relaxation responses to virodhamine. The CB(1) receptor antagonist SR 141716A (3 microM), but not the more CB(1)-selective blocker AM 251 (1 microM), attenuated the response, while two CB(2) receptor antagonists, SR 144528 (1 microM) and AM 630 (10 microM), had no effect. The novel antagonist for the putative endothelial 'abnormal-cannabidiol receptor', O-1918 (30 microM), inhibited virodhamine relaxations. Hence virodhamine may activate this novel receptor, which might also recognize SR 141716A. Inhibition of nitric oxide synthase (L-NAME 300 microM) did not affect relaxation to virodhamine but the responses were markedly reduced when tone was induced with 60 mM KCl, suggesting a role for the activation of K(+) channels. The Ca(2+)-activated K(+) channel (K(Ca)) blockers, apamin (50 nM) and charyb...Continue Reading

References

Mar 3, 1999·Journal of Medicinal Chemistry·R LanA Makriyannis
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·Z JáraiG Kunos
Mar 29, 2001·European Journal of Pharmacology·S KagotaM Kunitomo
Oct 19, 2001·British Journal of Pharmacology·R WhiteC R Hiley
Mar 19, 2002·The Journal of Physiology·David HarrisMichael D Randall
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Amy C PorterChristian C Felder
Jul 27, 2002·Orvosi hetilap·Zoltán Járai, György Kúnos
Aug 17, 2002·Pharmacology & Therapeutics·Michael D RandallVera Ralevic
Oct 16, 2002·Trends in Pharmacological Sciences·Rudi BusseArthur H Weston
Feb 28, 2003·Molecular Pharmacology·László OffertálerGeorge Kunos
Apr 25, 2003·British Journal of Pharmacology·W-S Vanessa Ho, C Robin Hiley
Jun 6, 2003·British Journal of Pharmacology·W-S Vanessa Ho, C Robin Hiley
Sep 4, 2003·The Journal of Biological Chemistry·Malcolm BeggGeorge Kunos
Feb 11, 2004·British Journal of Pharmacology·Saoirse E O'SullivanMichael D Randall
Mar 10, 2004·Biological Reviews of the Cambridge Philosophical Society·C Robin Hiley, William R Ford

❮ Previous
Next ❯

Citations

Mar 4, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Effimia GkoumassiJohan Zaagsma
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Thomas W Klein, Guy A Cabral
Oct 23, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Luciano De Petrocellis, Vincenzo Di Marzo
Feb 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Garry MilmanRaphael Mechoulam
Mar 12, 2013·Prostaglandins & Other Lipid Mediators·B M FonsecaN A Teixeira
May 26, 2012·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Marta Baranowska-KuczkoBarbara Malinowska
Jun 3, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Eric Murillo-Rodríguez
Sep 19, 2007·British Journal of Pharmacology·S P H Alexander, D A Kendall
Sep 19, 2007·British Journal of Pharmacology·E RybergP J Greasley
Aug 20, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M A StorrK A Sharkey
Dec 8, 2010·British Journal of Pharmacology·Christopher J GarlandKim A Dora
Jul 31, 2014·British Journal of Pharmacology·Alexander I Bondarenko
Aug 4, 2015·Pharmacology Research & Perspectives·Sarah K WalshCherry L Wainwright
Jan 24, 2013·European Journal of Pharmacology·Yousuf M AlSuleimani, C Robin Hiley
Aug 27, 2019·Current Pharmaceutical Design·Fabiana Piscitelli, Cristoforo Silvestri
Nov 17, 2020·Oxidative Medicine and Cellular Longevity·J A Garza-CervantesG García-Rivas
Aug 24, 2018·Biochemical Pharmacology·Carmen Del RíoEduardo Muñoz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.